Results of the recent FASTRACK II trial showed positive results for a noninvasive treatment for primary renal cell carcinoma. This first multicenter, nonsurgical phase 2 trial demonstrated a 100% local control rate with stereotactic body radiation therapy (SBRT), no cancer-related deaths, and a 99% rate of freedom from distant failure over a median follow-up of 43 months. The trial, which included patients who were inoperable or at risk of dialysis post-surgery, suggests SBRT as a promising alternative to surgery, particularly for large or centrally located tumors.
Reference: Doyle C. Stereotactic Body Radiation Therapy Demonstrates ‘Exceptional Control’ in Primary Renal Cell Carcinoma. Published October 30, 2023. Accessed November 6, 2023. https://ascopost.com/news/october-2023/stereotactic-body-radiation-therapy-demonstrates-exceptional-control-in-primary-renal-cell-carcinoma/
